Beactica Therapeutics AB

Russia
Kholbon, Zabaykalskiy (Transbaikal) Kray, Russia, 754 50

Company profile

Beactica Therapeutics AB company profile

Beactica Therapeutics AB is a precision oncology company committed to the fight against cancer. The company is advancing a pipeline of novel small molecule therapeutics to treat genetically defined cancers with significant unmet clinical need. Beactica’s approach is centered around targeting disease proteins with synthetic lethality vulnerabilities by applying its molecular interaction-based drug discovery engine to generate novel small molecule across synergistic modalities, including allosteric modulators and targeted protein degraders (PROTACs). Beactica deliver value to patients and shareholders by advancing its programmes into early clinical trials.

Business identity

Phone number
46 18 56 08 80
Operating status
Active
Company type
For Profit
Employee range
11-50 employees
Revenue range
$0-$1M
Founded
2006-01-01, Year

Headquarters

Postal code
754 50
Country code
RU
Continent
Europe

Capital profile

Funding and company signals

Funding rounds
9
Last funding
Series Unknown / 2019-06-04
Last equity funding
Series Unknown
Investors
6
Lead investors
2
Founders
1
Articles
5

Founders and investors

Founders

Per Källblad

Lead investors

European CommissionVinnova

Investors

Almi InvestEISMEAEuropean CommissionUnionenVinnova